XML 64 R24.htm IDEA: XBRL DOCUMENT
v3.20.1

Note 16 - Segment Data | 12 Months Ended
--- | ---
Mar. 31, 2020
Notes to Financial Statements |
Segment Reporting Disclosure [Text Block] | Note 16. Segment Data Segment information is prepared on the same basis that our CEO, who is our Chief Operating Decision Maker, manages the segments, evaluates financial results, and makes key operating decisions. We have four reportable segments: Sterilization and Disinfection Control, Instruments, Biopharmaceutical Development, and Continuous Monitoring (formerly Cold Chain Monitoring). When determining the reportable segments, we aggregated operating segments based on their similar economic and operating characteristics. During the year ended March 31, 2020, we exited the Cold Chain Packaging business, which resulted in Management ceasing to consider its results in its analysis of financial results and operational decision making. As of March 31, 2020, we no longer consider it a reportable segment. Results for the Cold Chain Packaging division are now presented within Corporate and Other and prior period amounts related to Cold Chain Packaging have been categorized and presented as Corporate and Other. The following tables set forth our segment information:
|  | Year Ended March 31, 2020 |
|  | Sterilization and Disinfection Control |  |  | Instruments |  |  | Biopharmaceutical Development |  |  | Continuous Monitoring |  |  | Corporate and Other |  |  | Total |
Revenues (1) |  | $ | 49,660 |  |  | $ | 37,984 |  |  | $ | 13,851 |  |  | $ | 13,729 |  |  | $ | 2,463 |  |  | $ | 117,687 |
Gross profit (loss) |  | $ | 35,758 |  |  | $ | 24,229 |  |  | $ | 382 |  |  | $ | 4,146 |  |  | $ | 418 |  |  | $ | 64,933 |
Reconciling items (2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (61,500 | )
Earnings before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 3,433 |
|  | Year Ended March 31, 2019 |
|  | Sterilization and Disinfection Control |  |  | Instruments |  |  | Biopharmaceutical Development |  |  | Continuous Monitoring |  |  | Corporate and Other |  |  | Total |
Revenues (1) |  | $ | 46,297 |  |  | $ | 36,125 |  |  | $ | -- |  |  | $ | 13,806 |  |  | $ | 6,907 |  |  | $ | 103,135 |
Gross profit |  | $ | 31,861 |  |  | $ | 22,866 |  |  | $ | -- |  |  | $ | 5,582 |  |  | $ | 607 |  |  | $ | 60,916 |
Reconciling items (2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (52,293 | )
Earnings before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 8,623 |
|  | Year Ended March 31, 2018 |
|  | Sterilization and Disinfection Control |  |  | Instruments |  |  | Biopharmaceutical Development |  |  | Continuous Monitoring |  |  | Corporate and Other |  |  | Total |
Revenues (1) |  | $ | 43,260 |  |  | $ | 34,104 |  |  | $ | -- |  |  | $ | 12,978 |  |  | $ | 5,837 |  |  | $ | 96,179 |
Gross profit |  | $ | 29,333 |  |  | $ | 20,395 |  |  | $ | -- |  |  | $ | 3,854 |  |  | $ | 1,037 |  |  | $ | 54,619 |
Reconciling items (2) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (54,318 | )
Earnings before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 301 |
| ( 1 ) | Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
| ( 2 ) | Reconciling items include selling, general and administrative, research and development, impairment of goodwill and long-lived assets, legal settlement, and nonoperating expenses.
We evaluate the performance of our operating segments based on revenues, organic revenues growth, and gross margin. The accounting policies of the operating segments are the same as those described in Note 1. "Description of Business and Summary of Significant Accounting Policies." The identifiable assets by segment disclosed in this note are those assets specifically identifiable within each segment and include inventories, accounts receivable, property, plant and equipment, net, right-of-use leased assets directly attributable to operating segments, goodwill, and intangible assets. Assets not attributed to reportable operating segments are corporate assets and are primarily comprised of cash and cash equivalents, assets related to our selling, general, and administrative functions, right-of-use assets related to selling, general and administrative functions, and prepaid income taxes. The following table sets forth capital expenditures by reportable segment:
|  | Sterilization and Disinfection Control |  |  | Instruments |  |  | Biopharmaceutical Development |  |  | Continuous Monitoring |  |  | Corporate and Other |  |  | Total |
Year ended March 31, 2020 |  | $ | 291 |  |  | $ | 165 |  |  | $ | 233 |  |  | $ | 201 |  |  | $ | 608 |  |  | $ | 1,498 |
Year ended March 31, 2019 |  |  | 384 |  |  |  | 56 |  |  |  | -- |  |  |  | 254 |  |  |  | 568 |  |  |  | 1,262 |
Year ended March 31, 2018 |  |  | 1,007 |  |  |  | 254 |  |  |  | -- |  |  |  | 483 |  |  |  | 1,055 |  |  |  | 2,799 |
The following table sets forth depreciation and amortization by reportable segment:
|  | Sterilization and Disinfection Control |  |  | Instruments |  |  | Biopharmaceutical Development |  |  | Continuous Monitoring |  |  | Corporate and Other |  |  | Total |
Year ended March 31, 2020 |  | $ | 902 |  |  | $ | 179 |  |  | $ | 358 |  |  | $ | 328 |  |  | $ | 11,223 |  |  | $ | 12,990 |
Year ended March 31, 2019 |  |  | 902 |  |  |  | 207 |  |  |  | -- |  |  |  | 272 |  |  |  | 8,047 |  |  |  | 9,428 |
Year ended March 31, 2018 |  |  | 823 |  |  |  | 263 |  |  |  | -- |  |  |  | 327 |  |  |  | 8,058 |  |  |  | 9,471 |
The following table sets forth total assets by reportable segment:
|  | March 31, 2020 |  |  | March 31, 2019 |
Sterilization and Disinfection Control |  | $ | 73,103 |  |  | $ | 74,230 |
Instruments |  |  | 31,025 |  |  |  | 30,911 |
Biopharmaceutical Development |  |  | 182,758 |  |  |  | -- |
Continuous Monitoring |  |  | 29,732 |  |  |  | 32,179 |
Corporate and Other |  |  | 103,588 |  |  |  | 19,447 |
Total |  | $ | 420,206 |  |  | $ | 156,767 |
The following table sets forth a summary of long-lived assets by geographic area. Long-lived assets exclude goodwill and intangible assets acquired in a business combination.
|  | As of March 31, |
|  | 2020 |  |  | 2019 |
United States |  | $ | 34,767 |  |  | $ | 22,974 |
Foreign |  |  | 1,240 |  |  |  | 574 |
Total long-lived assets |  | $ | 36,007 |  |  | $ | 23,548 |
Revenues from external customers are attributed to individual countries based upon locations to which the product is shipped or exported, as follows:
|  | Year Ended March 31, |
|  | 2020 |  |  | 2019 |  |  | 2018 |
United States |  | $ | 66,344 |  |  | $ | 64,828 |  |  | $ | 56,998 |
Foreign |  |  | 51,343 |  |  |  | 38,307 |  |  |  | 39,181 |
Total revenues |  | $ | 117,687 |  |  | $ | 103,135 |  |  | $ | 96,179 |
Revenues are shown based on the geographic location of our customers. No customer accounts for 10% or more of our revenues. No foreign country exceeds 10% of total revenues.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI http://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration